Cardiovascular Genomics Market by Product & Services (Consumables & Reagents, Testing Services, Instruments, Software & Bioinformatics Solutions), Test Type, Application, End User, and Geography — Global Forecast to 2035

Cardiovascular Genomics Market Size & Forecast

The global cardiovascular genomics market is estimated at USD 2.2 billion in 2025 and is projected to reach USD 10.9 billion by 2035, at a CAGR of 17.5% during the forecast period from 2025 to 2035.

The cardiovascular genomics market encompasses the comprehensive application of genetic and genomic technologies to understand, diagnose, prevent, and treat inherited and acquired cardiovascular diseases. This includes the identification of pathogenic variants, polygenic risk assessment, pharmacogenomic profiling, and clinical interpretation supported by advanced bioinformatics platforms. The discipline addresses a broad spectrum of conditions—ranging from inherited cardiomyopathies and arrhythmia syndromes to familial hypercholesterolemia and aortopathies—as well as polygenic contributions to prevalent conditions such as coronary artery disease and atrial fibrillation.

Key factors propelling this market include the rising global burden of cardiovascular diseases, which account for approximately 17.9 million deaths annually according to the World Health Organization, growing clinical adoption of precision medicine supported by Class I and Class IIa guideline recommendations, and the continuous decline in next-generation sequencing costs—from over USD 100 million per genome in 2001 to approximately USD 600–1,000 in 2024. The establishment of dedicated cardiogenetics clinics, expanding cascade screening programs, and increasing integration of polygenic risk scores into preventive cardiology are further reinforcing market growth.

The increasing recognition that 40–60% of cardiovascular disease risk is attributable to inherited genetic variants has placed genomics at the center of modern cardiovascular care. Diagnostic yields ranging from 25–80% depending on indication and phenotype, combined with guideline-driven testing recommendations for conditions such as hypertrophic cardiomyopathy (affecting 1 in 500 individuals) and familial hypercholesterolemia (affecting 1 in 250), are contributing to a steady rise in testing volumes across clinical settings.

Looking ahead, the cardiovascular genomics market is positioned for robust growth driven by the convergence of falling sequencing costs, AI-powered bioinformatics platforms, and an expanding evidence base for polygenic risk scoring in common cardiovascular conditions. As genomic testing transitions from specialized academic centers to mainstream clinical practice, the market is expected to witness significant opportunities across diagnostic, preventive, and pharmacogenomic applications.

Key Findings

• By Product & Services: The Consumables & Reagents Segment to Dominate the Cardiovascular Genomics Market in 2025
• By Test Type: The Targeted Gene Panels Segment to Dominate the Cardiovascular Genomics Market in 2025
• By Application: In 2025, the Diagnostic Testing Segment is Expected to Dominate the Cardiovascular Genomics Market
• By End User: The Clinical Diagnostic Laboratories Segment to Dominate the Cardiovascular Genomics Market in 2025
• By Geography: North America Dominates the Cardiovascular Genomics Market in 2025

Cardiovascular Genomics Market Growth Drivers and Market Insights

Click here to: Get Free Sample Pages of this Report

Rising Global Prevalence of Cardiovascular Diseases and Sudden Cardiac Death

Cardiovascular diseases continue to represent the single largest contributor to global mortality, creating sustained and growing demand for advanced diagnostic and risk assessment solutions, including genomic testing. According to the World Health Organization, cardiovascular diseases account for approximately 32% of all global deaths, with the prevalence of heart failure exceeding 64 million individuals and atrial fibrillation affecting nearly 60 million people worldwide. The burden of these conditions is expected to grow further, with atrial fibrillation cases projected to potentially double by 2050 as populations age and cardiometabolic risk factors become more widespread.

Inherited cardiovascular disorders represent a critical subset of this burden and are among the most compelling clinical rationales for genomic testing. Hypertrophic cardiomyopathy, the most common inherited cardiac condition, affects approximately 1 in 500 individuals globally. Dilated cardiomyopathy occurs in an estimated 1 in 250–400 individuals, while familial hypercholesterolemia—one of the most prevalent monogenic disorders—affects approximately 1 in 250 but remains significantly underdiagnosed, with fewer than 10% of affected individuals currently identified. Inherited arrhythmia syndromes, including long QT syndrome (approximately 1 in 2,000–2,500 individuals) and Brugada syndrome (approximately 1 in 2,000–5,000), collectively affect hundreds of thousands of people worldwide.

Sudden cardiac death adds a further and particularly urgent dimension to the market. In the United States alone, sudden cardiac death accounts for an estimated 350,000–450,000 deaths annually. Post-mortem genetic testing, or molecular autopsy, has gained increasing guideline support, with diagnostic yields of approximately 25–35% for the identification of causative pathogenic variants. These results support cascade screening of at-risk family members, enabling preventive interventions that can directly reduce future mortality. This dual clinical utility—clarifying cause of death while protecting living relatives—is a powerful driver of genomic testing adoption.

Growing Adoption of Precision Medicine in Cardiology

The shift toward precision medicine has become one of the most consequential drivers in the cardiovascular genomics market, as cardiology moves from uniform treatment pathways toward genotype-guided approaches for diagnosis, risk stratification, and therapeutic decision-making. Professional societies including the American Heart Association, the American College of Cardiology, and the Heart Rhythm Society have incorporated genetic testing recommendations into guidelines for multiple inherited cardiovascular conditions, with Class I or Class IIa recommendations now in place for several clinical scenarios spanning cardiomyopathies and inherited arrhythmia syndromes.

The clinical utility of cardiovascular genetic testing is well supported by consistent diagnostic yields across major indications. Pathogenic or likely pathogenic variants are identified in approximately 30–60% of patients with hypertrophic cardiomyopathy, 25–40% of patients with dilated cardiomyopathy, and 40–80% of individuals with well-phenotyped long QT syndrome. These yields translate into tangible clinical outcomes, including confirmation of diagnoses, guidance for implantable cardioverter-defibrillator placement, tailored pharmacotherapy, prognostic assessment, and cascade family screening.

The growth of dedicated cardiogenetics clinics and multidisciplinary care programs has further embedded precision medicine into cardiovascular practice. Academic medical centers and integrated health systems are increasingly building specialized programs that combine cardiology, genetic counseling, molecular genetics, and bioinformatics expertise, serving as hubs for both clinical implementation and translational research. As precision cardiology matures, these programs are expected to expand significantly in both number and scope.

Declining Costs and Increasing Accessibility of Next-Generation Sequencing

The dramatic reduction in sequencing costs has been a foundational enabler of cardiovascular genomics market growth, transforming genetic testing from an expensive research capability into a clinically accessible and cost-effective diagnostic tool. Whole genome sequencing costs have fallen from approximately USD 100 million in 2001 to below USD 600–1,000 in recent years, driven by advances in sequencing chemistry, higher throughput platforms, and more efficient bioinformatics pipelines. For cardiovascular-specific applications, targeted gene panel testing costs have declined from approximately USD 3,000–5,000 in the early 2010s to roughly USD 1,000–2,500 currently, while comprehensive panels covering 50–200 genes are now offered at price points comparable to, or lower than, single-gene testing costs a decade ago.

This cost evolution has meaningfully improved the value proposition of genetic testing, enabling broader clinical application beyond patients with highly penetrant hereditary conditions. Direct-to-consumer genetic testing has further expanded access, with cardiovascular risk assessments and pharmacogenomic panels now available at USD 100–300, increasing public awareness of genetic contributions to heart disease and building demand for confirmatory clinical testing. As sequencing costs continue to decline and platform accessibility improves, broader integration of genomic testing into routine cardiovascular and primary care workflows is expected to follow.

Cardiovascular Genomics Market Opportunity

Integration of Cardiovascular Genomics into Routine Clinical Workflows

The integration of cardiovascular genomics into routine clinical workflows represents one of the most significant near-term opportunities for market expansion. At present, the majority of cardiovascular genetic testing occurs within tertiary care settings and dedicated cardiogenetics clinics, reaching only a fraction of patients who meet clinical testing criteria. Embedding genomic testing into standard cardiology, primary care, and emergency medicine workflows could substantially increase testing volumes while supporting earlier diagnosis and intervention.

Electronic health record–based clinical decision support tools are a key enabler, capable of identifying eligible patients based on diagnoses, family history, and clinical findings, and streamlining test ordering, result tracking, and cascade screening coordination. Health systems that have implemented integrated genomic workflows have demonstrated meaningful improvements in guideline adherence and appropriate testing rates. Advances in rapid pharmacogenomic testing—such as CYP2C19 genotyping during percutaneous coronary intervention—and point-of-care applications for sudden cardiac arrest survivors represent additional opportunities to bring genomic decision-making directly into acute care settings.

Expanding Applications in Pharmacogenomics for Cardiovascular Drug Response

Pharmacogenomics for cardiovascular drug response is positioned for accelerated growth, supported by an expanding clinical evidence base, increasing CPIC guidance, and growing interest in preemptive testing models. CYP2C19-guided antiplatelet therapy is the most established application, with loss-of-function alleles present in approximately 30% of individuals and clinical evidence confirming that genotype-guided therapy reduces adverse cardiovascular outcomes following percutaneous coronary intervention. Statin pharmacogenomics, guided by SLCO1B1 variants associated with myopathy risk, represents an emerging opportunity given that statin intolerance affects an estimated 10–20% of patients and adherence remains a major challenge in lipid management.

Preemptive pharmacogenomic testing—generating and embedding genomic data into the electronic health record ahead of prescribing decisions—offers a paradigm shift with the potential to substantially expand testing volumes. Health systems implementing such programs have demonstrated clinical feasibility and utility, and cardiovascular pharmacogenomic variants are consistently among those included given the widespread prescription of cardiovascular medications. As implementation evidence grows and reimbursement coverage evolves, this application is expected to move progressively from pilot programs toward mainstream clinical deployment.

Development of Multi-Ancestry Polygenic Risk Scores for Diverse Populations

The development and validation of multi-ancestry polygenic risk scores represents an important opportunity at the intersection of health equity and market expansion. Most currently available PRSs have been developed predominantly from populations of European ancestry, and predictive accuracy in African, Asian, Hispanic, and other non-European populations is estimated to decline by approximately 20–50% or more compared with European cohorts—a limitation that constrains both the clinical utility and the global reach of PRS-based cardiovascular risk stratification.

Large-scale genomics initiatives including the All of Us Research Program, the PAGE consortium, and H3Africa are generating the diverse population data needed to address these gaps. Combined with methodological advances in multi-ancestry meta-analysis and machine learning approaches, these efforts are improving PRS portability across populations. From a market perspective, validated multi-ancestry PRSs open pathways into high-growth regions in Asia, Latin America, and Africa, while within established markets they align with increasing regulatory and payer emphasis on equitable precision medicine. Companies investing in this space are likely to gain competitive advantages as evidence requirements for diverse population performance become more formally embedded in regulatory and clinical adoption frameworks.

Cardiovascular Genomics Market Analysis: Top Market Opportunities

By Product & Services: The Consumables & Reagents Segment to Dominate the Cardiovascular Genomics Market in 2025

Based on product & services, the cardiovascular genomics market is segmented into consumables & reagents, testing services, instruments, and software & bioinformatics solutions. In 2025, the consumables & reagents segment is expected to account for the largest share of 40.0% of the cardiovascular genomics market. This segment is projected to reach USD 4.36 billion by 2035 from an estimated USD 0.87 billion in 2025, at a CAGR of 17.4% during the forecast period.

The dominant position of this segment reflects the inherently recurring and volume-driven nature of consumable usage across cardiovascular genomic workflows. NGS library preparation kits, target enrichment reagents, PCR consumables, enzymes, probes, and sample processing materials are required for every sample processed—across research, clinical diagnostics, biobanking, and drug discovery—making them a structurally stable and continuously expanding revenue contributor. The growing number of genetic tests performed, combined with rising biobanking initiatives and population-scale sequencing programs, is expected to sustain high consumable demand throughout the forecast period.

However, the software & bioinformatics solutions segment is expected to grow at the fastest CAGR of 21.1% during the forecast period, driven by the increasing data burden of whole-genome and whole-exome sequencing and growing demand for AI/ML-based variant annotation, polygenic risk scoring platforms, and cloud-based clinical decision support systems. As cardiovascular genomics shifts from research to routine clinical use, the need for scalable, automated, and clinically validated software infrastructure is accelerating faster than demand for hardware or laboratory reagents.

By Test Type: The Targeted Gene Panels Segment to Dominate the Cardiovascular Genomics Market in 2025

Based on test type, the cardiovascular genomics market is segmented into targeted gene panels, single gene testing, whole exome sequencing (WES), polygenic risk score (PRS) testing, pharmacogenomic testing, and whole genome sequencing (WGS). In 2025, the targeted gene panels segment is expected to account for the largest share of 35.8% of the cardiovascular genomics market. This segment is projected to reach USD 3.56 billion by 2035 from an estimated USD 0.78 billion in 2025, at a CAGR of 16.3% during the forecast period.

Targeted gene panels command the largest share because they offer the most practical balance between clinical utility, cost, turnaround time, and interpretability for cardiovascular disorders. By focusing on a well-defined set of high-confidence genes linked to cardiomyopathies, arrhythmias, familial hypercholesterolemia, and aortopathies, these panels generate highly actionable results with simpler bioinformatics requirements and less incidental data compared with WES or WGS. These attributes make targeted panels the preferred option for hospitals, diagnostic laboratories, and specialty cardiology centers for mainstream clinical testing.

However, polygenic risk score (PRS) testing is expected to register the fastest CAGR of 22.9% during the forecast period, as cardiovascular care broadens from rare disease diagnosis toward population-level risk prediction and prevention. As AI-driven analytics mature, large biobank datasets become more accessible, and precision medicine expands into primary care, the adoption of PRS testing for coronary artery disease, atrial fibrillation, and stroke risk stratification is accelerating well ahead of traditional diagnostic modalities.

By Application: In 2025, the Diagnostic Testing Segment to Dominate the Cardiovascular Genomics Market

Based on application, the cardiovascular genomics market is segmented into diagnostic testing, research applications, risk assessment & predictive testing, cascade/family screening, pharmacogenomics & drug response testing, and prenatal & newborn screening. In 2025, the diagnostic testing segment is expected to account for the largest share of 39.5% of the cardiovascular genomics market. This segment is projected to reach USD 3.73 billion by 2035 from an estimated USD 0.86 billion in 2025, at a CAGR of 15.7% during the forecast period.

The dominant position of the diagnostic testing segment reflects the rising prevalence of inherited and acquired cardiovascular disorders, increasing adoption of genetic testing in routine cardiology care, growing availability of targeted gene panels, and broad integration of genomic testing into hospitals, specialty clinics, and diagnostic laboratories for accurate disease identification and clinical decision support.

However, the risk assessment & predictive testing segment is expected to witness the fastest CAGR of 21.7% during the forecast period, driven by the shift toward preventive cardiology, growing use of polygenic risk scores, large-scale biobank initiatives, and rising adoption of genomics in population health screening and early risk stratification for conditions such as coronary artery disease and stroke.

By End User: The Clinical Diagnostic Laboratories Segment to Dominate the Cardiovascular Genomics Market in 2025

Based on end user, the cardiovascular genomics market is segmented into clinical diagnostic laboratories, hospitals & health systems, academic & research institutes, specialized cardiogenetics clinics, pharmaceutical & biotechnology companies, and direct-to-consumer/retail genetic testing companies. In 2025, the clinical diagnostic laboratories segment is expected to account for the largest share of 32.9% of the cardiovascular genomics market. This segment is projected to reach USD 3.46 billion by 2035 from an estimated USD 0.72 billion in 2025, at a CAGR of 17.0% during the forecast period.

Clinical diagnostic laboratories dominate the end-user landscape because they serve as primary hubs for high-volume cardiovascular genetic testing, with the automation, sequencing infrastructure, accreditation, and skilled workforce required to process large sample volumes efficiently. Most hospitals and cardiology centers outsource complex genomic testing to centralized labs rather than maintaining in-house capabilities, further concentrating demand in this segment.

However, the specialized cardiogenetics clinics segment is expected to register the fastest CAGR of 20.0% during the forecast period. As cardiovascular care becomes increasingly genetics-driven and multidisciplinary, these clinics—integrating cardiology with clinical genetics, genetic counseling, and family screening—are well-positioned to absorb the growing demand for comprehensive management of inherited heart diseases including cardiomyopathies, arrhythmias, and familial hypercholesterolemia.

Geographical Analysis

North America Dominates the Cardiovascular Genomics Market in 2025

Based on geography, the global cardiovascular genomics market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. In 2025, North America is expected to account for the largest share of 43.7% of the global cardiovascular genomics market. The North America cardiovascular genomics market is projected to reach USD 4.42 billion by 2035 from an estimated USD 0.95 billion in 2025, at a CAGR of 16.15% during the forecast period.

The region's leadership is underpinned by well-established healthcare infrastructure, high adoption of precision medicine, a strong concentration of leading genomics companies, large-scale biobanking initiatives, and robust funding for cardiovascular research. Widespread integration of genomics into clinical cardiology, favorable reimbursement policies for established indications, and high awareness among physicians and patients have further reinforced North America's dominant position in the market.

However, Asia-Pacific is expected to register the highest CAGR during the forecast period. Rapid growth in this region is driven by increasing healthcare investments, expanding genetic testing infrastructure, rising cardiovascular disease prevalence, government-supported genomics programs, and growing collaboration between global genomics companies and regional diagnostic players. Improving access to advanced sequencing technologies and the expansion of private diagnostic chains are accelerating market development across key Asia-Pacific countries.

Key Companies

Some of the prominent players operating in the global cardiovascular genomics market include Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), Quest Diagnostics (U.S.), Danaher Corporation (U.S.), Invitae Corporation (U.S.), GeneDx, LLC (U.S.), Blueprint Genetics Oy (Finland), Genomics plc (U.K.), Fulgent Genetics, Inc. (U.S.), Ambry Genetics Corporation (U.S.), Color Health, Inc. (U.S.), Centogene N.V. (Germany), Myriad Genetics, Inc. (U.S.), Praxis Genomics LLC (U.S.), PerkinElmer, Inc. (U.S.), Agilent Technologies (U.S.), and Oxford BioDynamics Plc (U.K.).

These companies have actively pursued strategic developments to strengthen their market positions, with the most prevalent strategies being partnerships, agreements & collaborations; product launches & enhancements; and geographic expansions.

Cardiovascular Genomics Market Research Summary

Key Questions Answered in the Report